Indalpine

Indalpine is a pharmaceutical drug that belongs to the class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). It was developed in the 1980s for the treatment of major depressive disorder and other mood disorders.

Mechanism of Action

Indalpine works by inhibiting the reuptake of serotonin (5-HT) in the brain, thereby increasing the levels of serotonin in the synaptic cleft. This action helps to alleviate symptoms of depression by enhancing serotonergic neurotransmission.

Clinical Use

Indalpine was primarily prescribed for the treatment of major depressive disorder. It was also investigated for its potential use in treating other conditions such as anxiety disorders and obsessive-compulsive disorder (OCD).

Side Effects

Common side effects of Indalpine include nausea, headache, insomnia, and sexual dysfunction. Like other SSRIs, it may also increase the risk of suicidal thoughts and behaviors, particularly in young adults and adolescents.

Withdrawal and Discontinuation

Abrupt discontinuation of Indalpine can lead to withdrawal symptoms such as dizziness, irritability, fatigue, and flu-like symptoms. It is recommended to taper off the medication gradually under the supervision of a healthcare provider.

Regulatory Status

Indalpine was withdrawn from the market due to concerns about its safety profile, particularly the risk of severe side effects such as hepatotoxicity and blood dyscrasias. As a result, it is no longer available for clinical use.

See Also

• Selective serotonin reuptake inhibitor
• Major depressive disorder
• Serotonin
• Antidepressant

External Links

-